MBX Biosciences (MBX) Operating Expenses (2023 - 2026)

MBX Biosciences has disclosed Operating Expenses across 4 years of filings, most recently posting $27.3 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $27.3 million, up 1748.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $57.1 million (up 149.2% YoY), and the FY2025 annual result was $98.1 million, up 2075.62% from the prior year.
• Operating Expenses came in at $27.3 million for Q1 2026 at MBX Biosciences, up from $25.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $27.3 million in Q1 2026 to a low of $363000.0 in Q4 2024.
• The 4-year median for Operating Expenses is $2.3 million (2025), against an average of $9.3 million.
• Across the five-year window, Operating Expenses sank 96.37% in 2024 and soared 7006.06% in 2025, its largest moves.
• MBX Biosciences' Operating Expenses stood at $10.0 million in 2023, then tumbled by 96.37% to $363000.0 in 2024, then jumped by 7006.06% to $25.8 million in 2025, then rose by 5.7% to $27.3 million in 2026.
• The last three Operating Expenses figures came in at $27.3 million (Q1 2026), $25.8 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.